ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,969.34
0.35%
US Tech 100
20,266.40
0.33%
다우존스 지수
44,296.51
0.97%
Bitcoin
97,891.00
0.02%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. 2seventy bio Inc (TSVT)

  7. 2seventy bio Inc (TSVT) 뉴스

2seventy bio Inc

2seventy bio Inc (TSVT)

NASDAQ
3.61
0.45
(14.24%)
마감 25 11월 6:00AM
15분 지연
3.61
-0.01
(-0.28%)
시간외 거래: 8:56AM
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

TSVT 뉴스

공식 뉴스 전용

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
21 11월 2024
TSVT (14.24%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
19 11월 2024
TSVT (14.24%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
13 11월 2024
TSVT (14.24%)

Form 8-K - Current report
Edgar (US Regulatory)
31 10월 2024
TSVT (14.24%)

Form 8-K - Current report
Edgar (US Regulatory)
25 9월 2024
TSVT (14.24%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
17 8월 2024
TSVT (14.24%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
15 8월 2024
TSVT (14.24%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
09 8월 2024
TSVT (14.24%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 8월 2024
TSVT (14.24%)

Form 8-K - Current report
Edgar (US Regulatory)
07 8월 2024
TSVT (14.24%)

TSVT Discussion

게시물 보기
Monksdream Monksdream 3 월 전
TSVT under $5
👍️0
Monksdream Monksdream 7 월 전
TSVT under $5
👍️0
Invest-in-America Invest-in-America 8 월 전
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 9 월 전
TSVT 10Q due March 5
👍️0
molee molee 10 월 전
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 11 월 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1
johnhancoque johnhancoque 1 년 전
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 1 년 전
C'mon man . What the heck . $2.00 now ? Really ?
👍️0

최근 히스토리

NASDAQ
TSVT
2seventy bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유